These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30446361)

  • 1. Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma.
    Back M; Jayamanne D; Brazier D; Bailey D; Hsiao E; Guo L; Wheeler H
    J Clin Neurosci; 2019 Jan; 59():68-74. PubMed ID: 30446361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy.
    Metz G; Jayamanne D; Wheeler H; Wong M; Cook R; Little N; Parkinson J; Kastelan M; Brown C; Back M
    BMC Neurol; 2022 Jan; 22(1):24. PubMed ID: 35027006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
    Back M; Jayamanne DT; Brazier D; Newey A; Bailey D; Schembri GP; Hsiao E; Khasraw M; Wong M; Kastelan M; Guo L; Clarke S; Wheeler H
    J Med Imaging Radiat Oncol; 2019 Apr; 63(2):272-280. PubMed ID: 30677248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
    Back M; Jayamanne D; Brazier D; Newey A; Bailey D; Schembri G; Hsiao E; Khasraw M; Wong M; Kastelan M; Brown C; Wheeler H
    Strahlenther Onkol; 2020 Jan; 196(1):31-39. PubMed ID: 31028406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volumetric Response and Survival of Patients With Bulky IDH-Mutated Grade 3 Glioma Managed With FET-FDG-Guided Integrated Boost IMRT.
    Mills D; Horsley P; Venkatasha V; Back M
    Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):343-352. PubMed ID: 38553362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing radiation dose to normal brain through a risk adapted dose reduction protocol for patients with favourable subtype anaplastic glioma.
    Back M; LeMottee M; Crasta C; Bailey D; Wheeler H; Guo L; Eade T
    Radiat Oncol; 2017 Mar; 12(1):46. PubMed ID: 28253929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
    Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
    World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics.
    Ruff MW; Uhm J
    Curr Treat Options Oncol; 2018 Oct; 19(12):61. PubMed ID: 30361986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
    Franceschi E; Tosoni A; De Biase D; Lamberti G; Danieli D; Pizzolitto S; Zunarelli E; Visani M; Di Oto E; Mura A; Minichillo S; Scafati C; Asioli S; Paccapelo A; Bartolini S; Brandes AA
    Oncologist; 2019 May; 24(5):664-670. PubMed ID: 30777895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma.
    Back MF; Jayamanne D; Back E; Kastelan M; Khasraw M; Wong M; Brown C; Wheeler H
    Cancer; 2019 Oct; 125(19):3457-3466. PubMed ID: 31251406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
    Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas.
    Hong JB; Roh TH; Kang SG; Kim SH; Moon JH; Kim EH; Ahn SS; Choi HJ; Cho J; Suh CO; Chang JH
    Cancer Res Treat; 2020 Oct; 52(4):1041-1049. PubMed ID: 32324987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.
    Kizilbash SH; Giannini C; Voss JS; Decker PA; Jenkins RB; Hardie J; Laack NN; Parney IF; Uhm JH; Buckner JC
    J Neurooncol; 2014 Oct; 120(1):85-93. PubMed ID: 24993250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
    Cairncross JG; Wang M; Jenkins RB; Shaw EG; Giannini C; Brachman DG; Buckner JC; Fink KL; Souhami L; Laperriere NJ; Huse JT; Mehta MP; Curran WJ
    J Clin Oncol; 2014 Mar; 32(8):783-90. PubMed ID: 24516018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.
    McNamara MG; Jiang H; Lim-Fat MJ; Sahebjam S; Kiehl TR; Karamchandani J; Coire C; Chung C; Millar BA; Laperriere N; Mason WP
    Can J Neurol Sci; 2017 May; 44(3):288-294. PubMed ID: 28488951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-grade and anaplastic oligodendroglioma.
    Van Den Bent MJ; Bromberg JE; Buckner J
    Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse Infiltrating Oligodendroglioma and Astrocytoma.
    van den Bent MJ; Smits M; Kros JM; Chang SM
    J Clin Oncol; 2017 Jul; 35(21):2394-2401. PubMed ID: 28640702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
    Sorge C; Li R; Singh S; Reddy AT; Solomon DA; Perry A; Friedman GK
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28696020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.